[go: up one dir, main page]

BRPI0801239A2 - use of one or more benzopyranones, pharmaceutical composition and method for the prevention or treatment of monoamine oxidase-associated diseases, disorders and disorders - Google Patents

use of one or more benzopyranones, pharmaceutical composition and method for the prevention or treatment of monoamine oxidase-associated diseases, disorders and disorders

Info

Publication number
BRPI0801239A2
BRPI0801239A2 BRPI0801239-3A BRPI0801239A BRPI0801239A2 BR PI0801239 A2 BRPI0801239 A2 BR PI0801239A2 BR PI0801239 A BRPI0801239 A BR PI0801239A BR PI0801239 A2 BRPI0801239 A2 BR PI0801239A2
Authority
BR
Brazil
Prior art keywords
disorders
treatment
prevention
pharmaceutical composition
benzopyranones
Prior art date
Application number
BRPI0801239-3A
Other languages
Portuguese (pt)
Inventor
Queiroz Emerson Ferreira
Original Assignee
Ache Lab Farmaceuticos Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Lab Farmaceuticos Sa filed Critical Ache Lab Farmaceuticos Sa
Priority to BRPI0801239-3A priority Critical patent/BRPI0801239A2/en
Priority to PCT/BR2009/000089 priority patent/WO2009121155A2/en
Publication of BRPI0801239A2 publication Critical patent/BRPI0801239A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

USO DE UM OU MAIS BENZOPIRANONAS, COMPOSIçãO FARMACêUTICA E MéTODO DE PREVENçãO OU TRATAMENTO DE DOENçAS, DISFUNçõES E DISTúRBIOS ASSOCIADOS A MONOAMINO OXIDASE. A presente invenção tem por objeto o uso de compostos benzopiranonas de fórmula (1) na fabricação de um medicamento útil no tratamento de doenças, disfunções e distúrbios associados a monoaminoxidase, composições farmacêuticas contendo tais compostos e método para prevenir ou tratar as mesmas.USE OF ONE OR MORE BENZOPYRANANS, PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTION OR TREATMENT OF MONOAMINO OXIDASE DISEASES, DISORDERS AND DISORDERS. The present invention relates to the use of benzopyranone compounds of formula (1) in the manufacture of a medicament useful in the treatment of monoaminoxidase-associated diseases, disorders and disorders, pharmaceutical compositions containing such compounds and method for preventing or treating them.

BRPI0801239-3A 2008-04-01 2008-04-01 use of one or more benzopyranones, pharmaceutical composition and method for the prevention or treatment of monoamine oxidase-associated diseases, disorders and disorders BRPI0801239A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BRPI0801239-3A BRPI0801239A2 (en) 2008-04-01 2008-04-01 use of one or more benzopyranones, pharmaceutical composition and method for the prevention or treatment of monoamine oxidase-associated diseases, disorders and disorders
PCT/BR2009/000089 WO2009121155A2 (en) 2008-04-01 2009-04-01 Use of one or more benzopyranones, phamaceutical composmon and method for preventing or treating diseases, dysfunctions and disturbances associated to monoamine oxidase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0801239-3A BRPI0801239A2 (en) 2008-04-01 2008-04-01 use of one or more benzopyranones, pharmaceutical composition and method for the prevention or treatment of monoamine oxidase-associated diseases, disorders and disorders

Publications (1)

Publication Number Publication Date
BRPI0801239A2 true BRPI0801239A2 (en) 2009-11-17

Family

ID=41135963

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0801239-3A BRPI0801239A2 (en) 2008-04-01 2008-04-01 use of one or more benzopyranones, pharmaceutical composition and method for the prevention or treatment of monoamine oxidase-associated diseases, disorders and disorders

Country Status (2)

Country Link
BR (1) BRPI0801239A2 (en)
WO (1) WO2009121155A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102329312A (en) * 2011-07-26 2012-01-25 苏州宝泽堂医药科技有限公司 Method for purifying schaftoside
KR20150019505A (en) * 2013-08-14 2015-02-25 대화제약 주식회사 Pharmaceutical Compositions comprising flavone-6-C-glucose derivatives for treating or preventing neuropsychiatric disorders
HRP20201466T1 (en) 2014-09-16 2021-03-05 Roar Holding, Llc Energy drinks and other nutritional aids derived from agave-based spirits
KR101818084B1 (en) * 2015-04-14 2018-01-15 대구가톨릭대학교산학협력단 A composition comprising extract of Lycopodiella cernua or compound isolated therefrom for preventing or treating of Alzheimer disease-Ⅱ
EP3349748B1 (en) 2015-09-19 2023-11-01 Indus Biotech Private Limited Compositions comprising feenugreek extracts and methods for producing them
WO2020112898A1 (en) 2018-11-26 2020-06-04 Roar Holding Llc Methods to improve beverage quality
WO2021225343A1 (en) * 2020-05-06 2021-11-11 한국한의학연구원 Composition for preventing or treating cognitive disorder, comprising iris lactea extract
CN115461051B (en) * 2020-09-11 2023-11-28 李宗谚 Pharmaceutical composition and use thereof for treating parkinson's disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317071D0 (en) * 1993-08-17 1993-09-29 Univ Strathclyde Flavonoids
JPH0873360A (en) * 1994-09-01 1996-03-19 Yoshihide Hagiwara Suppressing agent against brain nerve cell injury
US6806257B1 (en) * 1999-10-20 2004-10-19 Board Of Trustees Of Southern Illinois University Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
EP1377286A1 (en) * 2001-02-20 2004-01-07 Randy H. Ziegler Treatment of schizophrenia
US7763588B2 (en) * 2003-06-13 2010-07-27 The Salk Institute For Biological Studies Method for increasing cognitive function and neurogenesis
BRPI0602106B8 (en) * 2006-05-25 2021-05-25 Ache Laboratorios Farm S/A process for preparing a product based on passionflower incarnata l.
WO2008011538A2 (en) * 2006-07-19 2008-01-24 The Salk Institute For Biological Studies Methods of using flavonoids to enhance memory

Also Published As

Publication number Publication date
WO2009121155A3 (en) 2009-11-26
WO2009121155A2 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
BRPI0801239A2 (en) use of one or more benzopyranones, pharmaceutical composition and method for the prevention or treatment of monoamine oxidase-associated diseases, disorders and disorders
BRPI0619153A8 (en) substituted 4-aminopyrroltriazine derivatives, and pharmaceutical composition
UA95644C2 (en) Pyridizinone derivative, pharmaceutical composition and treatment method
BRPI0609785B8 (en) Piperazine-substituted benzothiophenes, pharmaceutical composition, process for producing a pharmaceutical composition, use of piperazine-substituted benzothiophenes or a salt thereof, and, process for producing piperazine-substituted benzothiophenes
BRPI0607017B8 (en) pharmaceutical composition comprising memantine and donezepil, and their use for the treatment of snc-related conditions
MX2007015863A (en) Sphingosine kinase inhibitors.
SE0301010D0 (en) Novel compounds
TW200612892A (en) Novel compounds
SE0301009D0 (en) Novel compounds
CO6150162A2 (en) PIRROLOPIRIMIDINAS FOR PHARMACEUTICAL COMPOSITIONS
NO20090321L (en) Use of substituted 2-aminotyethralines for the manufacture of a drug for the prevention, relief and / or treatment of various types of pain
BRPI0809977A8 (en) USE OF A COMPOUND, COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING IT
BR112012021652A2 (en) compound use thereof and pharmaceutical composition
JO2686B1 (en) compounds
WO2007068894A3 (en) Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
MX2009000657A (en) Compositions and methods for the treatment of mucositis.
TW200745003A (en) Novel compounds
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
UA104988C2 (en) Novel pyrone-indole derivatives and process for their preparation
UA84048C2 (en) Sulfonamide derivatives for the treatment of diseases, process for the preparation thereof (variants), pharmaceutical composition based thereon
TW200630336A (en) Novel compounds
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
BR112012021656A2 (en) compound use thereof and pharmaceutical composition
TW200621690A (en) Novel compounds
BRPI0508051A (en) heteroarylaminopyrazole derivatives usable for the treatment of diabetes

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL